In addition, the results of our study indicate that CEA level changes are strongly associated with therapy response, supporting the recommendation that CEA and LDH assessment should be considered as part of standard of care for patients with previously untreated advanced NSCLC treated with platinum‐based chemotherapy. Here, CEACAM5 is linked to non-small cell lung carcinoma.